HDAC9 and rheumatoid arthritis: While HDAC modulators (inhibitors/activators) show therapeutic potential for RA, current single-target agents are limited by poor isoform selectivity, off-target toxicity, and inadequate attenuation of RA's multi-pathway pathology.